Clinical study on biapenem in respiratory tract infections

Abstract

We evaluated the clinical efficacy and safety of biapenem (BIPM), a new carbapenem, at a dose of 300mg twice daily for 5-20 days in 16 patients with respiratory tract infections, including 13 cases of bacterial pneumonia, one of chronic bronchitis, one of mycoplasma pneumonia and one of interstitial pneumonia. The clinical efficacy in the 14 evaluable cases was excellent in 4 patients, good in 9, poor in one. The efficacy rate was 92.9%.
A side effect was observed in one patient, who showed abdominal pain and diarrhea. Elevation of eosinophils was found in one case.